This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Quetiapine in Social Anxiety Disorder

This study has been completed.
Information provided by:
Duke University Identifier:
First received: September 20, 2005
Last updated: December 18, 2006
Last verified: March 2006
The purpose of the study is to examine the effectiveness and tolerability of quetiapine for the treatment of social anxiety disorder (SAD). The hypothesis is that quetiapine will be effective and well-tolerated for patients with social anxiety disorder.

Condition Intervention Phase
Social Anxiety Disorder Drug: quetiapine Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quetiapine in Social Anxiety Disorder

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • Brief Social Phobia Scale (BSPS)

Secondary Outcome Measures:
  • Clinical Global Impressions of Severity (CGI-S)
  • Clinical Global Impressions of Improvement (CGI-I)
  • Social Phobia Inventory (SPIN)
  • Hospital Anxiety and Depression Scale (HADS)
  • Connor Davidson Resilience Scale (CD-RISC)
  • Sheehan Disability Inventory (SDI)
  • Barnes Akathisis Scale (BAS)
  • Simpson-Angus Scale (SAS)

Estimated Enrollment: 15
Study Start Date: March 2004
Estimated Study Completion Date: February 2006
Detailed Description:
This is an eight week, randomized, double-blind, placebo-controlled trial of quetiapine (100-400 mg/day)in social anxiety disorder.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult outpatients 18-65 years of age
  • primary diagnosis of social anxiety disorder, using DSM-IV criteria
  • minimum CGI severity score of 4 at baseline
  • minimum BSPS score of 20 at baseline
  • written informed consent
  • negative serum pregnancy test for women of childbearing potential

Exclusion Criteria:

  • current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition
  • any current primary anxiety disorder other than SAD or current primary depression
  • history of substance abuse or dependence with the last 6 months
  • suicide risk or serious suicide attempt within the last year
  • clinically significant medical condition or laboratory abnormality
  • women of childbearing potential who are unwilling to practice an acceptable method of contraception
  • concomitant medication use for psychotropic purposes
  • history of hypersensitivity to quetiapine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00215254

United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Duke University
Principal Investigator: Jonathan Davidson, M.D. Duke University
  More Information Identifier: NCT00215254     History of Changes
Other Study ID Numbers: 5639-04-3R0
Study First Received: September 20, 2005
Last Updated: December 18, 2006

Keywords provided by Duke University:
social anxiety disorder
pilot study

Additional relevant MeSH terms:
Anxiety Disorders
Phobic Disorders
Pathologic Processes
Mental Disorders
Quetiapine Fumarate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs processed this record on September 21, 2017